Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of lenalidomide with DA-EPOCH-R in MYC-associated B-cell lymphomas has completed, and results hav…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Nemtabrutinib, Bortezomib, and Rituximab for WM [Phase 2]
Phase 2 clinical trial at Seoul National University Hospital evaluating nemtabrutinib in combination with bortezomib and rituximab for Walde…
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies [Phase 2]
Phase 2 trial of Brexucabtagene Autoleucel in adults with rare B-cell malignancies has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating ixazomib citrate with rituximab in indolent B-cell non-Hodgkin lymphoma has posted results.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
An observational study evaluating the efficacy and safety of zanubrutinib in participants with Waldenström macroglobulinemia is currently re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma [Phase 1, Phase 2]
This document outlines an ongoing Phase 1/2 dose-escalation and dose-expansion trial of MDX2003 in multiple lymphoma types, including Walden…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers [Phase 1]
Phase 1 study of oral LOXO-338 in advanced blood cancers is ongoing, with status listed as active but not recruiting.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
A Mayo Clinic-sponsored clinical trial (HALT) is evaluating strategies to manage hypertension and prevent cardiovascular adverse events in p…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Spanish Registry of Patients With IgM Monoclonal Gammopathies
A Spanish registry study updating IgM monoclonal gammopathies is recruiting, focusing on patients with Waldenström macroglobulinemia.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of APG-3288 in Relapsed/Refractory Blood Cancers [Phase 1]
Phase 1 study of APG-3288 in relapsed/refractory hematologic cancers; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial of ABBV-383 for relapsed or refractory Waldenström macroglobulinemia is listed and currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of SGR-1505 in Mature B-Cell Neoplasms [Phase 1]
Schrödinger's SGR-1505 is being evaluated in a Phase 1 trial across multiple mature B-cell neoplasms and is currently recruiting. The study …
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
A Dana-Farber Cancer Institute-led clinical study recruiting to investigate molecular progression and clinical outcomes in MGUS, smoldering …
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia [Phase 4]
Phase 4 clinical trial comparing RCD versus BCD regimens in newly diagnosed Waldenström macroglobulinemia has completed.
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM [Phase 4]
A Phase 4 trial assessing the efficacy of a TCD regimen followed by TP maintenance in newly diagnosed Waldenström macroglobulinemia has comp…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia [Phase 2]
A Phase 2 clinical trial evaluating the combination of zanubrutinib, ixazomib, and dexamethasone in treatment-naive Waldenström macroglobuli…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia [Phase 4]
A Phase 4 clinical trial comparing autologous stem cell transplantation to conventional chemotherapy in high-risk Waldenström macroglobuline…
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 clinical trial evaluating bendamustine, rituximab, and acalabrutinib in Waldenström macroglobulinemia is currently active and not re…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment [Phase 2]
This update summarizes a Phase 2 trial of zanubrutinib (BGB-3111) in participants with previously treated B-cell lymphomas intolerant to pri…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical trial registry update for the RUBIN platform extension focusing on hematologic malignancies. It is currently recruiting for conditi…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial of the oral BTK inhibitor LOXO-305 (pirtobrutinib) in patients with previously treated chronic lymphocy…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
A retrospective-prospective Italian study evaluating real-world use and outcomes of zanubrutinib (Brukinsa) in Waldenström's macroglobulinem…
-
CLINICAL_TRIALS trial_result · 2026-01-02Clinical Trial Update: Detection of Recurrent Mutations in Waldenström's Disease [NA]
A completed clinical trial investigated recurrent mutations in Waldenström macroglobulinemia.
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia [Phase 2]
A Phase 2 clinical trial is investigating Sonrotoclax alone and in combination with Zanubrutinib in adults with Waldenström macroglobulinemi…